Lung Cancer Drug Pipeline Update

  • ID: 1197058
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.

There are today 552 companies plus partners developing 809 lung cancer drugs in 884 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 267 drugs. Lung Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 431 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 406 out of the 410 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the READ MORE >

Note: Product cover images may vary from those shown
2 of 2

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown




Our Clients

  • Varian Medical Systems, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Amgen Inc.
  • Almac Diagnostics Group
  • Boston Biomedical Inc.